WallStreetZenWallStreetZen

NASDAQ: ABEO
Abeona Therapeutics Inc Stock

$4.21+0.28 (+7.12%)
Updated Sep 29, 2023
ABEO Price
$4.21
Fair Value Price
$4.49
Market Cap
$104.22M
52 Week Low
$2.19
52 Week High
$5.80
P/E
-2.96x
P/B
11.15x
P/S
20.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.57M
Earnings
-$36.37M
Gross Margin
100%
Operating Margin
-1,004.26%
Profit Margin
-1,019.4%
Debt to Equity
4.73
Operating Cash Flow
-$43M
Beta
1.14
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ABEO Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABEO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ABEO ($4.21) is undervalued by 6.17% relative to our estimate of its Fair Value price of $4.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ABEO ($4.21) is not significantly undervalued (6.17%) relative to our estimate of its Fair Value price of $4.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABEO due diligence checks available for Premium users.

Be the first to know about important ABEO news, forecast changes, insider trades & much more!

ABEO News

Valuation

ABEO fair value

Fair Value of ABEO stock based on Discounted Cash Flow (DCF)
Price
$4.21
Fair Value
$4.49
Undervalued by
6.17%
ABEO ($4.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABEO ($4.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABEO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ABEO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.96x
Industry
13.67x
Market
12.37x

ABEO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
11.15x
Industry
5.09x
ABEO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ABEO's financial health

Profit margin

Revenue
$3.5M
Net Income
-$16.7M
Profit Margin
-475.8%
ABEO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABEO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$53.6M
Liabilities
$44.2M
Debt to equity
4.73
ABEO's short-term assets ($44.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABEO's short-term assets ($44.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABEO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ABEO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.3M
Investing
$5.2M
Financing
$6.6M
ABEO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ABEO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ABEO$104.22M+7.12%-2.96x11.15x
INO$104.28M+2.37%-0.60x0.62x
MIST$103.49M+2.31%-2.26x2.56x
CUE$103.41M-0.86%-1.81x2.25x
ORMP$105.12M+3.98%-5.12x0.69x

Abeona Therapeutics Stock FAQ

What is Abeona Therapeutics's quote symbol?

(NASDAQ: ABEO) Abeona Therapeutics trades on the NASDAQ under the ticker symbol ABEO. Abeona Therapeutics stock quotes can also be displayed as NASDAQ: ABEO.

If you're new to stock investing, here's how to buy Abeona Therapeutics stock.

What is the 52 week high and low for Abeona Therapeutics (NASDAQ: ABEO)?

(NASDAQ: ABEO) Abeona Therapeutics's 52-week high was $5.80, and its 52-week low was $2.19. It is currently -27.41% from its 52-week high and 92.24% from its 52-week low.

How much is Abeona Therapeutics stock worth today?

(NASDAQ: ABEO) Abeona Therapeutics currently has 24,755,873 outstanding shares. With Abeona Therapeutics stock trading at $4.21 per share, the total value of Abeona Therapeutics stock (market capitalization) is $104.22M.

Abeona Therapeutics stock was originally listed at a price of $68,350.00 in Dec 31, 1997. If you had invested in Abeona Therapeutics stock at $68,350.00, your return over the last 25 years would have been -99.99%, for an annualized return of -32.15% (not including any dividends or dividend reinvestments).

How much is Abeona Therapeutics's stock price per share?

(NASDAQ: ABEO) Abeona Therapeutics stock price per share is $4.21 today (as of Sep 29, 2023).

What is Abeona Therapeutics's Market Cap?

(NASDAQ: ABEO) Abeona Therapeutics's market cap is $104.22M, as of Sep 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Abeona Therapeutics's market cap is calculated by multiplying ABEO's current stock price of $4.21 by ABEO's total outstanding shares of 24,755,873.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.